9 1 2 3 6
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 2.6 Breast Cancer (Dove Med Press)
- 3.9 Clin Epidemiol
- 3.3 Cancer Manag Res
- 3.9 Infect Drug Resist
- 3.6 Clin Interv Aging
- 4.8 Drug Des Dev Ther
- 2.8 Int J Chronic Obstr
- 8.0 Int J Nanomed
- 2.3 Int J Women's Health
- 3.2 Neuropsych Dis Treat
- 4.0 OncoTargets Ther
- 2.2 Patient Prefer Adher
- 2.8 Ther Clin Risk Manag
- 2.7 J Pain Res
- 3.3 Diabet Metab Synd Ob
- 4.3 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.9 Pharmgenomics Pers Med
- 3.5 Risk Manag Healthc Policy
- 4.5 J Inflamm Res
- 2.3 Int J Gen Med
- 4.1 J Hepatocell Carcinoma
- 3.2 J Asthma Allergy
- 2.3 Clin Cosmet Investig Dermatol
- 3.3 J Multidiscip Healthc
已发表论文
转铁蛋白修饰的纳米结构脂质载体用于多功能纳米药物的 DNA 和阿霉素的共同给药
Authors Han Y, Zhang Y, Li D, Chen Y, Sun J, Kong F
Published Date August 2014 Volume 2014:9(1) Pages 4107—4116
DOI http://dx.doi.org/10.2147/IJN.S67770
Received 15 May 2014, Accepted 20 June 2014, Published 25 August 2014
Background: Nanostructured lipid carriers (NLC), composed of solid and liquid lipids, and surfactants are potentially good colloidal drug carriers. The aim of this study was to develop surface-modified NLC as multifunctional nanomedicine for codelivery of enhanced green fluorescence protein plasmid (pEGFP) and doxorubicin (DOX).
Methods: Two different nanocarriers: pEGFP- and DOX-loaded NLC, and solid lipid nanoparticles (SLN) were prepared. Transferrin-containing ligands were used for the surface coating of the vectors. Their average size, zeta potential, and drug encapsulation capacity were evaluated. In vitro transfection efficiency of the modified vectors was evaluated in human alveolar adenocarcinoma cell line (A549 cells), and in vivo transfection efficiency of the modified vectors was evaluated in a mouse bearing A549 cells model.
Results: Transferrin-modified DOX and pEGFP coencapsulated NLC (T-NLC) has a particle size of 198 nm and a +19 mV surface charge. The in vitro cell viabilities of the T-NLC formulations were over 80% compared with the control. T-NLC displayed remarkably greater gene transfection efficiency and enhanced antitumor activity than DOX- and pEGFP-coencapsulated SLN in vivo.
Conclusion: The results demonstrate that T-NLC noticeably enhanced antitumor activity through the combination of gene therapy with chemotherapy. Also coating of active transferrin improved the lung cancer cell-targeting of the carriers. In summary, the novel gene and drug delivery system offers a promising strategy for the treatment of lung cancer.
Keywords: multifunctional delivery system, active targeting, transferrin modification, solid lipid nanoparticles
Methods: Two different nanocarriers: pEGFP- and DOX-loaded NLC, and solid lipid nanoparticles (SLN) were prepared. Transferrin-containing ligands were used for the surface coating of the vectors. Their average size, zeta potential, and drug encapsulation capacity were evaluated. In vitro transfection efficiency of the modified vectors was evaluated in human alveolar adenocarcinoma cell line (A549 cells), and in vivo transfection efficiency of the modified vectors was evaluated in a mouse bearing A549 cells model.
Results: Transferrin-modified DOX and pEGFP coencapsulated NLC (T-NLC) has a particle size of 198 nm and a +19 mV surface charge. The in vitro cell viabilities of the T-NLC formulations were over 80% compared with the control. T-NLC displayed remarkably greater gene transfection efficiency and enhanced antitumor activity than DOX- and pEGFP-coencapsulated SLN in vivo.
Conclusion: The results demonstrate that T-NLC noticeably enhanced antitumor activity through the combination of gene therapy with chemotherapy. Also coating of active transferrin improved the lung cancer cell-targeting of the carriers. In summary, the novel gene and drug delivery system offers a promising strategy for the treatment of lung cancer.
Keywords: multifunctional delivery system, active targeting, transferrin modification, solid lipid nanoparticles
